Business
Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
PRT3789 monotherapy and combination with docetaxel escalation enrollment is complete and the Company plans to present updated results in the second half of 2025 Enrollment of the Phase 1 study of Prelude’s once daily, oral SMARCA2 degrader, PRT7732 is advancing rapidly, and an initial data update is anticipated in the second half of 2025 Current cash runway into the second quarter of 2026 with $103.1 million in cash, cash equivalents, restricted cash and marketable securities as of March 31, 202
About this update from Prelude Therapeutics Incorporated
[{"type":"image","alt":"Prelude Therapeutics, Incorporated","displaySize":"","headline":null,"caption":"Prelude Therapeutics, Incorporated","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":103,"url":"https://media.zenfs.com/en/globenewswire.com/8835d8a0be4b67686e42408eafbca555"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/9HVZo7WrFLmSMiAVkGF1.A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/8835d8a0be4b67686e42408eafbca555","width":300,"height":103}},"lazy":false},{"type":"text","content":"PRT3789 monotherapy and combination with docetaxel escalation enrollment is complete and the Company plans to present updated results in the second half of 2025","length":160,"tagName":"p"},{"type":"text","content":"Enrollment of the Phase 1 study of Prelude’s once daily, oral SMARCA2 degrader, PRT7732 is advancing rapidly, and an initial data update is anticipated in the second half of 2025","length":178,"tagName":"p"},{"type":"text","content":"Current cash runway into the second quarter of 2026 with $103.1 million in cash, cash equivalents, restricted cash and marketable securities as of March 31, 2025","length":161,"tagName":"p"},{"type":"text","content":"WILMINGTON, Del., May 06, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for first quarter ended March 31, 2025, and provided an update on its clinical development pipeline and other corporate developments.","length":316,"tagName":"p"},{"type":"text","content":"“The first quarter of 2025 represented another strong period of execution across our organization,” stated Kris Vaddi, Ph.D., Chief Executive Officer of Prelude. “We are making rapid progress with the development of our SMARCA2 degraders and are on track to determine the most optimal path forward for the overall program as we continue to strengthen our knowledge and understanding of potential opportunities for these novel, first-in-class drug candidates in highly aggressive SMARCA4 mutated cancers.”","length":504,"tagName":"p"},{"type":"text","content":"Continued Vaddi, “Additionally, we were very pleased to present at the most recent American Association for Cancer Research Annual Meeting, the first preclinical data from our highly selective, oral KAT6A degrad...